Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 4,082 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid treatment Clear all
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Intraoperative Methadone Administration for Improved Pain Control in Spinal Fusion Patients

NCT02989597
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Methadone Hydrochloride, Standard pain regimen, Spinal Fusion Surgery, Dexamethasone, Ketamine, Remifentanil, Sufentanil
Drug · Other · Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease

NCT00388362
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Sirolimus, Prednisone
Drug
Lead sponsor
Stanford University
Other
Eligibility
13 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia

NCT00227942
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Depression
Interventions
Estrogen Replacement Therapy, Zolpidem, placebo
Drug
Lead sponsor
Hadine Joffe, MD
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer

NCT00182741
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, mitoxantrone hydrochloride, prednisone
Dietary Supplement · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 9, 2026, 9:58 AM EDT
Not listed Phase 3 Interventional

Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma

NCT00014339
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
Wobe-Mugos E, melphalan, prednisone, quality-of-life assessment
Drug · Procedure
Lead sponsor
Medsearch
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 9, 2026, 9:58 AM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

NCT03500445
View directory record Official record
Conditions
Myeloma, Multiple Myeloma
Interventions
Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 9, 2026, 9:58 AM EDT
Recruiting Phase 4 Interventional

Dextenza in the Post-op Management of Vitreoretinal Surgeries

NCT04371445
View directory record Official record
Conditions
Vitreoretinal Surgery, Ocular Inflammation, Post-operative Pain, Post-Operative Inflammation
Interventions
Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 9, 2026, 9:58 AM EDT
Terminated Phase 2 Interventional Results available

Estradiol and Progesterone in Hospitalized COVID-19 Patients

NCT04865029
View directory record Official record
Conditions
Covid19
Interventions
Placebo injection and placebo pill, Estradiol Cypionate 5 mg/ml, Progesterone 200 mg Oral Capsule
Other · Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 9, 2026, 9:58 AM EDT
Recruiting Phase 2 Interventional

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

NCT04776395
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Dexamethasone, Iberdomide Hydrochloride, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 9, 2026, 9:58 AM EDT
Not listed Not applicable Interventional

Randomized Control Trial (RCT) of Early Palliative Care for HCC

NCT02556619
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Early Palliative Care/Symptom Control
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

NCT00004112
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Los Angeles, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 9, 2026, 9:58 AM EDT
Recruiting Phase 2 Interventional

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

NCT07085728
View directory record Official record
Conditions
Myeloma Multiple
Interventions
Cyclophosphamide, Bortezomib (VELCADE), Dexamethasone, Daratumumab-hyaluronidase
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

NCT00806819
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
40
States / cities
Downy, California • Fountain Valley, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss

NCT00004912
View directory record Official record
Conditions
Cachexia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
megestrol acetate, physical therapy
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
6
States / cities
North Little Rock, Arkansas • Long Beach, California • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Oct 9, 2026, 9:58 AM EDT
Active, not recruiting Phase 2 Interventional

Ixazomib Maintenance Study in Patients With AL Amyloidosis

NCT03618537
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Ixazomib, Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
8
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

NCT04484337
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL, Topical Non-steroidal anti-inflammatory drug (NSAID), Topical steroid, Topical NSAID placebo, Recombinant human hyaluronidase PH20 (rHuPH20), Topical steroid placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Orlando, Florida • Las Vegas, Nevada • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer

NCT00976339
View directory record Official record
Conditions
Breast Cancer
Interventions
Cholecalciferol
Drug
Lead sponsor
Katherine D. Crew
Other
Eligibility
21 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

NCT00520767
View directory record Official record
Conditions
Primary Systemic Amyloidosis, Light Chain Deposition Disease
Interventions
bortezomib, dexamethasone, melphalan, microarray analysis, flow cytometry, laboratory biomarker analysis, quality-of-life assessment
Drug · Genetic · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
7
States / cities
Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 9, 2026, 9:58 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1

NCT01890772
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Peginterferon alfa-2a, Ribavirin, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Timothy Morgan, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
Long Beach, California • Minneapolis, Minnesota • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults

NCT06268301
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Budesonide
Drug
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissue in the "Bra Strap Fat" Region

NCT04089722
View directory record Official record
Conditions
Brassiere Strap Fat (BSF), Bra Strap Fat (BSF)
Interventions
Deoxycholic Acid
Drug
Lead sponsor
Juva Skin & Laser Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Menopause Effects on Vascular Function

NCT03236545
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
No to Low Endogenous Estrogen, Estradiol
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma

NCT00059839
View directory record Official record
Conditions
Lymphoma
Interventions
doxorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, vinblastine sulfate, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
136
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 9, 2026, 9:58 AM EDT
Terminated Phase 2 Interventional Results available

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

NCT00372996
View directory record Official record
Conditions
Breast Neoplasms
Interventions
CP-751,871, exemestane, Fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
33
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 9, 2026, 9:58 AM EDT